United States - English - NLM (National Library of Medicine)

cadila pharmaceuticals limited - folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8) - folic acid 1 mg - folic acid, usp is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. folic acid, usp is contraindicated in patients who have shown previous intolerance to the drug.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 50 mg/ml - oral liquid, suspension - excipient ingredients: benzoic acid; glycerol; citric acid; sodium chloride; purified water; sodium citrate dihydrate; propylene glycol; xylitol; sodium cyclamate; microcrystalline cellulose; carmellose sodium; flavour - treatment of chronic cholestatic liver diseases.

United States - English - NLM (National Library of Medicine)

method pharmaceuticals, llc - folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8) - folic acid 1 mg - folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. folic acid is contraindicated in patients who have shown previous intolerance to the drug.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8) - folic acid 1 mg - folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. folic acid is contraindicated in patients who have shown previous intolerance to the drug.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8) - folic acid 1 mg - folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. folic acid is contraindicated in patients who have shown previous intolerance to the drug.

Australia - English - Department of Health (Therapeutic Goods Administration)

biotech pharmaceuticals pty ltd - benzoic acid,salicylic acid -

United States - English - NLM (National Library of Medicine)

leo pharma inc. - azelaic acid (unii: f2vw3d43yt) (azelaic acid - unii:f2vw3d43yt) - finacea gel, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. limitations of use although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated. none. risk summary azelaic acid is minimally absorbed systemically following topical route of administration, and maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)]. in animal reproduction studies, embryofetal toxicity was noted when azelaic acid was administered orally during the period of organogenesis at doses 162, 19, and 65 times the maximum recommended human dose (mrhd) in rats, rabbits, and monkeys, respectively. maternal toxicity was noted at these doses but no malformations were observed in these embryofetal developmental studies (see data). the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. data animal data dermal embryofetal developmental toxicology studies have not been performed with azelaic acid, 15% gel. oral embryofetal developmental studies were conducted with azelaic acid in rats, rabbits, and cynomolgus monkeys. azelaic acid was administered during the period of organogenesis in all three animal species. embryotoxicity was observed in rats, rabbits, and monkeys at oral doses of azelaic acid that generated some maternal toxicity. embryotoxicity was observed in rats given 2500 mg/kg/day [162 times the mrhd based on body surface area (bsa) comparison], rabbits given 150 or 500 mg/kg/day (19 or 65 times the mrhd based on bsa comparison) and cynomolgus monkeys given 500 mg/kg/day (65 times the mrhd based on bsa comparison) azelaic acid. no malformations were observed in the oral embryofetal developmental studies conducted in rats, rabbits and cynomolgus monkeys. an oral peri- and post-natal developmental study was conducted in rats. azelaic acid was administered from gestational day 15 through day 21 postpartum up to a dose level of 2500 mg/kg/day. embryotoxicity was observed in rats at an oral dose of 2500 mg/kg/day (162 times the mrhd based on bsa comparison) that generated some maternal toxicity. in addition, slight disturbances in the post-natal development of fetuses was noted in rats at oral doses that generated some maternal toxicity (500 and 2500 mg/kg/day; 32 and 162 times the mrhd based on bsa comparison). no effects on sexual maturation of the fetuses were noted in this study. risk summary azelaic acid is naturally present in human milk. when used as prescribed, azelaic acid is unlikely to be absorbed through the skin in clinically relevant amounts to cause a change in azelaic acid concentration in milk or milk production; therefore, breastfeeding is not expected to result in exposure of the infant to finacea gel. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for finacea gel and any potential adverse effects on the breastfed child from finacea gel or from the underlying maternal condition. the safety and effectiveness of finacea gel have not been established in pediatric patients. clinical studies of finacea gel did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects.

United States - English - NLM (National Library of Medicine)

leo pharma inc. - azelaic acid (unii: f2vw3d43yt) (azelaic acid - unii:f2vw3d43yt) - finacea foam, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. none. risk summary azelaic acid is minimally absorbed systemically following topical route of administration, and maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)]. in animal reproduction studies, embryofetal toxicity was noted when azelaic acid was administered orally during the period of organogenesis at doses 162, 19, and 65 times the maximum recommended human dose (mrhd) in rats, rabbits, and monkeys, respectively. maternal toxicity was noted at these doses but no malformations were observed in these embryofetal developmental studies (see data ). the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarria

United States - English - NLM (National Library of Medicine)

key therapeutics - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), benzoic acid (unii: 8skn0b0mim) (benzoic acid - unii:8skn0b0mim), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), hyoscyamine (unii: px44xo846x) (hyoscyamine - unii:px44xo846x) - u r i s e d™ is indicated for the relief of discomfort of the lower urinary tract caused by hypermotility resulting from inflammation or diagnostic procedures and in the treatment of cystitis, urethritis, and trigonitis when caused by organisms which maintain or produce an acid urine and are susceptible to formaldehyde. glaucoma, urinary bladder neck obstruction, pyloric or duodenal obstruction, or cardiospasm. hypersensitivity to any of the ingredients. a dependence on the use of u r i s e d™ has not been reported and due to the nature of its ingredients, abuse of u r i s e d™ is not expected.

United States - English - NLM (National Library of Medicine)

newton laboratories, inc. - benzoic acid (unii: 8skn0b0mim) (benzoic acid - unii:8skn0b0mim), berberis vulgaris root bark (unii: 1th8q20j0u) (berberis vulgaris root bark - unii:1th8q20j0u), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), lytta vesicatoria (unii: 3q034ro3bt) (lytta vesicatoria - unii:3q034ro3bt), centaurea benedicta (unii: 6l5zl09795) (centaurea benedicta - unii:6l5zl09795), ceanothus americanus leaf (unii: 25b1y14t8n) (ceanothus americanus leaf - unii:25b1y14t8n), chelidonium majus (u - formulated for symptoms associated with toxicity such as fatigue and sluggish elimination.